Pharmacological advances and therapeutic applications of niclosamide in cancer and other diseases
- PMID: 40153934
- DOI: 10.1016/j.ejmech.2025.117527
Pharmacological advances and therapeutic applications of niclosamide in cancer and other diseases
Abstract
Niclosamide, an FDA-approved drug traditionally used to treat parasitic infections, has garnered remarkable attention for its diverse pharmacological properties, suggesting potential therapeutic utility in oncology and a range of other diseases. This review offers an in-depth analysis of the chemical features and pharmacokinetics of niclosamide, underscoring the role of its salt forms and derivatives in enhancing bioavailability and therapeutic effectiveness. Emerging breakthroughs in nanotechnology have enabled the generation of advanced formulations capable of improving the safety and efficacy of niclosamide, addressing the challenges posed by its poor water solubility. Further, the review explores the intriguing molecular mechanisms driving niclosamide anticancer activity, highlighting its ability to act as a potent mitochondrial uncoupler and precisely modulate critical signal pathways that regulate cell proliferation, apoptosis, and inflammation. In cancer treatment, niclosamide has showcased compelling effects against various malignancies, offering marked potential in overcoming multidrug resistance, particularly in the resistant forms of leukemia and ovarian cancer. Additionally, the drug's versatility broadens its therapeutic potential beyond oncology, encompassing viral infections, metabolic disorders, and anti-inflammatory applications. By integrating the current literature, this review seeks to illuminate the pharmacological and clinical progress of niclosamide, hence emphasizing its promise as a multi-targeted therapeutic agent. As research evolves, niclosamide is poised to play a pivotal role in cancer therapy and the treatment of other complex diseases, reinforcing the necessity for continued clinical exploration and innovation.
Keywords: Anticancer agent; Cancer therapy; Clinical applications; Nanotechnology; Niclosamide; Pharmacology.
Copyright © 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.Cancer Lett. 2014 Jul 10;349(1):8-14. doi: 10.1016/j.canlet.2014.04.003. Epub 2014 Apr 13. Cancer Lett. 2014. PMID: 24732808 Free PMC article. Review.
-
Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug.Biomed Pharmacother. 2022 Nov;155:113789. doi: 10.1016/j.biopha.2022.113789. Epub 2022 Oct 8. Biomed Pharmacother. 2022. PMID: 36271567 Review.
-
Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.Adv Healthc Mater. 2025 May;14(14):e2404818. doi: 10.1002/adhm.202404818. Epub 2025 Feb 23. Adv Healthc Mater. 2025. PMID: 39988865 Free PMC article. Review.
-
Optimizing Niclosamide for Cancer Therapy: Improving Bioavailability via Structural Modification and Nanotechnology.Cancers (Basel). 2024 Oct 21;16(20):3548. doi: 10.3390/cancers16203548. Cancers (Basel). 2024. PMID: 39456642 Free PMC article. Review.
-
Polyanhydride Copolymer-Based Niclosamide Nanoparticles for Inhibiting Triple-Negative Breast Cancer: Metabolic Responses and Synergism with Paclitaxel.ACS Appl Mater Interfaces. 2024 Dec 25;16(51):70362-70377. doi: 10.1021/acsami.4c17961. Epub 2024 Dec 12. ACS Appl Mater Interfaces. 2024. PMID: 39666980
Cited by
-
Valine-Niclosamide for Treatment of Androgen Receptor Splice Variant-Positive Hepatocellular Carcinoma.Cancers (Basel). 2025 Jul 31;17(15):2535. doi: 10.3390/cancers17152535. Cancers (Basel). 2025. PMID: 40805231 Free PMC article.
-
A Strategic Antimetastatic Solution for Bone-Targeting Prostate Cancer via Nanoengineered Niclosamide.Nano Lett. 2025 Jul 30;25(30):11515-11519. doi: 10.1021/acs.nanolett.5c02826. Epub 2025 Jul 14. Nano Lett. 2025. PMID: 40657731 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials